David Bearss

David Bearss

Company: Biolexis Therapeutics

Job title: Co-Founder & Chairman

Seminars:

Patient Centric Development: Exploring Oral Obesity Therapeutics to Move Away from Injectable Peptides 4:50 pm

Explore enabling the development of oral obesity therapeutics that achieve bioavailability and efficacy comparable to injectable peptides Analyze the underlying mechanisms by which oral therapeutics modulate metabolic pathways and appetite suppression to induce weight loss, highlighting recent innovations in drug delivery systems Explore data comparing the efficacy, safety, and patient adherence of oral obesity therapeutics…Read more

day: Conference Day One

Panel Discussion: The Obesity Race on the Manufacturing Floor – Exploring Supply Challenges with Innovations in Discovery 2:40 pm

Examining supply chain challenges associated with peptides, including raw material shortages and complex manufacturing processes, and how these impact the availability of GLP-1 drugs compared to other therapeutic classes Analyzing the disparity between the rapidly increasing demand for GLP-1 receptor agonists and the current manufacturing capacity, highlighting how this affects market supply and patient access…Read more

day: Conference Day One

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.